187 related articles for article (PubMed ID: 29763709)
1. Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.
Harmer JA; Keech AC; Veillard AS; Skilton MR; Watts GF; Celermajer DS;
Diabetes Res Clin Pract; 2018 Jul; 141():156-167. PubMed ID: 29763709
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
Harmer JA; Keech AC; Veillard AS; Skilton MR; Marwick TH; Watts GF; Meredith IT; Celermajer DS;
Atherosclerosis; 2015 Sep; 242(1):295-302. PubMed ID: 26233916
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Keating GM
Am J Cardiovasc Drugs; 2011 Aug; 11(4):227-47. PubMed ID: 21675801
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
Hiukka A; Westerbacka J; Leinonen ES; Watanabe H; Wiklund O; Hulten LM; Salonen JT; Tuomainen TP; Yki-Järvinen H; Keech AC; Taskinen MR
J Am Coll Cardiol; 2008 Dec; 52(25):2190-7. PubMed ID: 19095138
[TBL] [Abstract][Full Text] [Related]
7. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Keating GM; Croom KF
Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
[TBL] [Abstract][Full Text] [Related]
9. Relations of lipid parameters, other variables with carotid intima-media thickness and plaque in the general Chinese adults: an observational study.
Hou Q; Li S; Gao Y; Tian H
Lipids Health Dis; 2018 May; 17(1):107. PubMed ID: 29747638
[TBL] [Abstract][Full Text] [Related]
10. Lipids and lipoprotein ratios: contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitus.
Shah AS; Urbina EM; Khoury PR; Kimball TR; Dolan LM
J Clin Lipidol; 2013; 7(5):441-5. PubMed ID: 24079285
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
Tanaka A; Yoshida H; Nanasato M; Oyama JI; Ishizu T; Ajioka M; Ishiki R; Saito M; Shibata Y; Kaku K; Maemura K; Higashi Y; Inoue T; Murohara T; Node K
Int J Cardiol; 2018 Nov; 271():331-335. PubMed ID: 29803341
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study.
Patti AM; Nikolic D; Magan-Fernandez A; Giglio RV; Castellino G; Chianetta R; Citarrella R; Corrado E; Provenzano F; Provenzano V; Montalto G; Rizvi AA; Rizzo M
Diabetes Res Clin Pract; 2019 Mar; 149():163-169. PubMed ID: 30759365
[TBL] [Abstract][Full Text] [Related]
13. Fatty liver is an independent predictor of early carotid atherosclerosis.
Pais R; Giral P; Khan JF; Rosenbaum D; Housset C; Poynard T; Ratziu V;
J Hepatol; 2016 Jul; 65(1):95-102. PubMed ID: 27129836
[TBL] [Abstract][Full Text] [Related]
14. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
15. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes.
Basu A; Jenkins AJ; Zhang Y; Stoner JA; Klein RL; Lopes-Virella MF; Garvey WT; Lyons TJ;
Atherosclerosis; 2016 Jan; 244():93-100. PubMed ID: 26600440
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive measurement of carotid extra-media thickness: associations with cardiovascular risk factors and intima-media thickness.
Skilton MR; Sérusclat A; Sethu AH; Brun S; Bernard S; Balkau B; Moulin P; Bonnet F
JACC Cardiovasc Imaging; 2009 Feb; 2(2):176-82. PubMed ID: 19356553
[TBL] [Abstract][Full Text] [Related]
18. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
19. Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes.
Leinonen ES; Salonen JT; Salonen RM; Koistinen RA; Leinonen PJ; Sarna SS; Taskinen MR
Diabetes Care; 2002 Oct; 25(10):1807-12. PubMed ID: 12351482
[TBL] [Abstract][Full Text] [Related]
20. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
